Compare Boston Scientific Corporation (BSX) vs Tidewater Inc (TDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Tidewater Inc — how do they compare? Boston Scientific Corporation trades at $43.57 (market cap $66.37B), while Tidewater Inc trades at $73.47 (market cap $3.68B). The key difference: Boston Scientific Corporation is far larger — about 18× Tidewater Inc's market cap, and Tidewater Inc is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | TDW | |
|---|---|---|
Market Cap | $66.37B | $3.68B |
Sector | Health | Utilities |
52-Week High | $108.14 | $91.12 |
52-Week Low | $42.63 | $46.32 |
Enterprise Value | $75.94B | $3.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Tidewater (TDW) trades at $74.35, up 1.34% today, with a bullish technical outlook driven by moving averages and ADX signals. Recent earnings show volatility with Q1 2026 missing estimates at $0.12 versus $0.75 expected, though Q3 2025 beat expectations. The company maintains strong profitability with a 22.16% net margin and robust cash flow from operations of $379.11M in 2025. News highlights include FTAI Infrastructure's acquisition of Tidewater Logistics in June 2026, potentially impacting operations.
The stock presents a mixed outlook; valuation metrics like a P/E of 12.47 suggest potential undervaluation, but earnings misses and a 'Hold' analyst consensus (61.54% hold ratings) indicate caution. Key risks include execution challenges in offshore support services and oil market volatility. Upside hinges on reversing recent earnings underperformance and capitalizing on industry acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
